Liomont and Oncobiologics partner to launch Biosimilars in Mexico
Cranbury, NJ – June 26, 2014 — Oncobiologics, Inc. and Laboratorios Liomont S.A. de C.V. announced today a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market. The scope of the agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics.
Under the agreement, Liomont, a leading Mexico City-based pharmaceutical company, will provide Oncobiologics with upfront licensing and development milestone payments, as well as royalties once the medicines are commercialized. Oncobiologics will oversee global clinical trials and will provide commercial supply manufacturing for launch in the Mexican market.
“This partnership is an important step toward introducing high-quality biotherapeutics to Mexico. Oncobiologics represents an ideal partner for Liomont’s entry into the biologics market. Together, we believe we can offer Mexican patients affordable therapeutics for serious diseases,” said Alfredo Rimoch, CEO of Liomont.
“Liomont is a leader in small-molecule pharmaceuticals development, production and commercialization in Mexico, and we are excited to partner with them to bring important biologics to Mexico. We are making excellent progress with the development of our biosimilar products and look forward to launching clinical programs very soon,” commented Oncobiologics Founder & CEO, Pankaj Mohan, Ph.D.
Financial terms were not disclosed.